Ifebemtinib (tosylate)

[1]Laszlo, V., et al., (2019) . The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma. Journal of molecular medicine (Berlin, Germany), 97 (2), 231–242. |[2]Verheijen, R. B., et al., (2019) . Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520. Targeted oncology, 14 (1), 67–74.|[3]Tiede, S., et al., (2018) . The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer. Oncogenesis, 7 (9), 73. |[4]Marabelle, A., et al., (2020) . Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. The Lancet. Oncology, 21 (10), 1353–1365.